<DOC>
	<DOCNO>NCT01957709</DOCNO>
	<brief_summary>This pilot clinical trial study effect recombinant interferon gamma tissue treat patient soft tissue sarcoma . Interferon gamma may interfere growth tumor cell .</brief_summary>
	<brief_title>Recombinant Interferon Gamma Treating Patients With Soft Tissue Sarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether systemic administration interferon ( IFN ) gamma ( recombinant interferon gamma ) increase class I major histocompatibility complex ( MHC ) expression synovial sarcoma ( SS ) myxoid/round cell liposarcoma ( MRCL ) tumor . SECONDARY OBJECTIVES : I . To determine whether systemic administration IFN gamma increase class II MHC expression SS MRCL tumor . II . To examine change immune response MRCL SS examine change immune infiltrates , antibody response antigen specific T cell response IFN gamma treatment . OUTLINE : Patients receive recombinant interferon gamma subcutaneously ( SC ) every 7 day 4 week surgery thrice weekly 2 week surgery . After completion study , patient follow 2 week post-surgery .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<mesh_term>Liposarcoma , Myxoid</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>A diagnosis synovial sarcoma myxoid/round cell liposarcoma A superficial tumor easily safely accessible research biopsy consider resection biopsy tumor part standard care recent pathology Zubrod performance status '02 ' Karnofsky score &gt; 60 % No treatment systemic anticancer treatment ( chemotherapy biologics ) within 2 week start interferon gamma Patients history coronary artery disease must normal stress test within 180 day start IFN gamma Must metformin least 2 week prior start IFN gamma No use full dose , therapeutic anticoagulation ; however , low dose warfarin catheter prophylaxis acetylsalicylic acid acceptable No thrombotic event within 6 month ( deep vein thrombosis , pulmonary embolism ) start IFN gamma Active infection require oral intravenous antibiotic Pregnant woman , nurse mother , men woman reproductive ability unwilling use effective contraception abstinence ; woman childbearing potential must negative pregnancy test within two week prior entry Serum creatinine &gt; 1.5 mg/dL glomerular filtration rate &lt; 50 Serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 150 IU &gt; 3 x upper limit normal Bilirubin &gt; 1.6 mg/dL Prothrombin time &gt; 1.5 x control Known central nervous system ( CNS ) metastasis ; CNS metastasis treat patient may participate otherwise good trial candidate Current treatment steroid ( must discontinue 1 week start IFN gamma ) Hemoglobin A1C &gt; 8.5 % Uncontrolled hypertension , blood pressure ( BP ) &gt; 150/100 mmHg ; patient elevate BP may enroll BP correct Cancer/testis antigen 1B ( NYESO1 ) specific T cell therapy within 1 year start trial New ( &lt; 6 month ) cardiac arrhythmia ( electrocardiogram [ EKG ] perform within 2 week start IFN gamma ) History clinically significant congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>